Brought to you by 
CTI licenses rights to Chroma’s tosedostat; deal ends with CTI gaining full rights in new agreement
28 Oct 2014
Executive Summary
Cell Therapeutics Inc. (CTI) and Chroma Therapeutics Ltd. (oncology and inflammation treatments) have entered into an agreement to co-develop and commercialize Chroma’s Phase I/II leukemia candidate tosedostat. CTI gets exclusive rights in North, Central, and South America, while Chroma retains rights in the rest of the world.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CTI licenses rights to Chroma’s tosedostat; deal ends with CTI gaining full rights in new agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice